CN102083971B - 修饰的因子ⅶ多肽及其应用 - Google Patents

修饰的因子ⅶ多肽及其应用 Download PDF

Info

Publication number
CN102083971B
CN102083971B CN200980121895.1A CN200980121895A CN102083971B CN 102083971 B CN102083971 B CN 102083971B CN 200980121895 A CN200980121895 A CN 200980121895A CN 102083971 B CN102083971 B CN 102083971B
Authority
CN
China
Prior art keywords
fvii
polypeptide
amino acid
fvii polypeptide
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980121895.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102083971A (zh
Inventor
E·L·麦迪逊
C·萨诺斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gc Biopharmaceutical Co
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Priority to CN201510387292.3A priority Critical patent/CN105039291A/zh
Publication of CN102083971A publication Critical patent/CN102083971A/zh
Application granted granted Critical
Publication of CN102083971B publication Critical patent/CN102083971B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200980121895.1A 2008-04-11 2009-04-10 修饰的因子ⅶ多肽及其应用 Active CN102083971B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510387292.3A CN105039291A (zh) 2008-04-11 2009-04-10 修饰的因子vii多肽及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12402108P 2008-04-11 2008-04-11
US61/124,021 2008-04-11
PCT/US2009/002248 WO2009126307A2 (en) 2008-04-11 2009-04-10 Factor vii polypeptides that are modified and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510387292.3A Division CN105039291A (zh) 2008-04-11 2009-04-10 修饰的因子vii多肽及其应用

Publications (2)

Publication Number Publication Date
CN102083971A CN102083971A (zh) 2011-06-01
CN102083971B true CN102083971B (zh) 2015-08-05

Family

ID=40872757

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510387292.3A Pending CN105039291A (zh) 2008-04-11 2009-04-10 修饰的因子vii多肽及其应用
CN200980121895.1A Active CN102083971B (zh) 2008-04-11 2009-04-10 修饰的因子ⅶ多肽及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510387292.3A Pending CN105039291A (zh) 2008-04-11 2009-04-10 修饰的因子vii多肽及其应用

Country Status (23)

Country Link
US (4) US8519103B2 (enExample)
EP (4) EP2687596B1 (enExample)
JP (3) JP2011517942A (enExample)
KR (1) KR101623602B1 (enExample)
CN (2) CN105039291A (enExample)
AU (1) AU2009234390B2 (enExample)
BR (1) BRPI0911060B1 (enExample)
CA (1) CA2721038C (enExample)
CO (1) CO6331368A2 (enExample)
DK (2) DK2281037T3 (enExample)
EA (2) EA024760B1 (enExample)
ES (3) ES2560236T3 (enExample)
HU (1) HUE026937T2 (enExample)
IL (2) IL208373A (enExample)
MX (2) MX344220B (enExample)
MY (1) MY161581A (enExample)
NZ (1) NZ588322A (enExample)
PL (1) PL2281037T3 (enExample)
PT (1) PT2281037E (enExample)
SG (2) SG193779A1 (enExample)
SI (1) SI2281037T1 (enExample)
TW (2) TWI465247B (enExample)
WO (1) WO2009126307A2 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AU2007307260B2 (en) 2006-07-05 2013-02-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
UA101155C2 (ru) * 2007-04-13 2013-03-11 Каталист Байосайенс, Инк. Модифицированный полипептид фактора vii (fvii) и его применение
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
ES2524974T3 (es) 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
SI2591006T1 (sl) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US20140046277A1 (en) * 2011-04-15 2014-02-13 Gamma Therapeutics, Inc. Fast-clotting wound dressings
WO2012149463A1 (en) * 2011-04-29 2012-11-01 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules with enhanced half life and methods of use
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
CN109535245A (zh) * 2012-02-14 2019-03-29 奥普科生物制品有限公司 长效凝血因子和生产它们的方法
WO2013156488A2 (en) 2012-04-16 2013-10-24 Leverton Licence Holdings Limited Optimised subcutaneous therapeutic agents
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
EP2906693A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
CA3185756A1 (en) 2012-12-24 2014-07-03 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CN103397009B (zh) * 2013-08-16 2015-06-03 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
AU2014336252A1 (en) 2013-10-15 2016-04-07 Novo Nordisk Health Care Ag Coagulation factor VII polypeptides
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
AR099328A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
RS60706B1 (sr) * 2014-05-26 2020-09-30 Academisch Ziekenhuis Leiden Prohemostatski proteini za lečenje krvarenja
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3325516B1 (en) 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
WO2018005716A2 (en) * 2016-07-01 2018-01-04 Denali Therapeutics Inc. Albumin variants for enhanced serum half-life
US20210284715A1 (en) * 2017-02-06 2021-09-16 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
EP3679127A1 (en) * 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
MX2020003351A (es) 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
MX2020003596A (es) 2017-10-04 2020-07-22 Avidity Biosciences Inc Composiciones de acido nucleico-polipeptido y usos de las mismos.
MA51583A (fr) * 2018-01-04 2020-11-11 Avidity Biosciences Inc Molécules d'acide nucléique hétéroduplex et leurs utilisations
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
WO2020010189A1 (en) * 2018-07-06 2020-01-09 Children's Medical Center Corporation Methods and compositions for analyzing platelets by mass cytometry
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020247818A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
CA3142283A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
CN114728044A (zh) * 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
JP7677978B2 (ja) * 2019-12-30 2025-05-15 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド 遺伝子変異ライブラリーを構築する方法
JP7759719B2 (ja) * 2020-02-27 2025-10-24 オムロン株式会社 流量測定装置
JP7705950B2 (ja) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド 細胞を増殖する方法
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件
US12385818B2 (en) 2023-02-14 2025-08-12 Saudi Arabian Oil Company Modeling gas desorption in a subsurface reservoir
CN118126161B (zh) * 2024-03-26 2025-10-24 福州大学 一种凝血因子FXIa的多肽抑制剂及其在抗凝治疗方面的应用
CN119372186B (zh) * 2024-12-30 2025-04-15 深圳市卫光生物制品股份有限公司 一种重组人凝血因子vii的纯化方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
EP1644504A1 (en) * 2003-06-19 2006-04-12 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited FACTOR VII OR VIIa GLA DOMAIN VARIANTS
WO2007022512A3 (en) * 2005-08-19 2007-10-04 Neose Technologies Inc Glycopegylated factor vii and factor viia
WO2007031559A3 (en) * 2005-09-14 2007-11-08 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
WO2009090215A1 (en) * 2008-01-18 2009-07-23 Ge Healthcare Uk Limited Multiplex cell signalling assay
CN102083971A (zh) * 2008-04-11 2011-06-01 催化剂生物科学公司 修饰的因子ⅶ多肽及其应用

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
WO1998035689A1 (en) * 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE19937219A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ES2449224T3 (es) 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Administración subcutánea del Factor de coagulación VII
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
CA2406583A1 (en) 2000-05-10 2001-11-15 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
PL204888B1 (pl) 2000-09-13 2010-02-26 Novo Nordisk Healthcare Ag Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
BR0113854A (pt) * 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
EP1325113B1 (en) 2000-10-02 2010-04-21 Novo Nordisk Health Care AG Factor vii glycoforms
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
PL365293A1 (en) 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
JP4336771B2 (ja) * 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US20040133930A1 (en) * 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
WO2002077263A2 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
KR20030096292A (ko) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
KR20040080940A (ko) 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
US20030134298A1 (en) * 2001-07-03 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
PL368119A1 (en) 2001-10-02 2005-03-21 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
US20030143219A1 (en) * 2001-10-09 2003-07-31 Madison Edwin L Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon
JP3862996B2 (ja) 2001-10-31 2006-12-27 帝人ファイバー株式会社 ポリトリメチレンテレフタレートフィラメント糸およびその製造方法
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003044179A2 (en) 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
IL162618A0 (en) 2001-12-21 2005-11-20 Novo Nordisk As Liquid composition of modified factor vii polypeptides
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
EP1361284A1 (en) 2002-05-10 2003-11-12 Direvo Biotech AG Process for generating sequence-specific proteases by directed evolution and use thereof
AU2003269880A1 (en) 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
CA2489596A1 (en) 2002-06-14 2003-12-24 Dyax Corporation Protein analysis
PT1517710E (pt) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Glicoformas do factor vii peguilado
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
WO2004005471A2 (en) 2002-07-02 2004-01-15 Dendreon Corporation Serine protease 16
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ES2339393T3 (es) 2002-09-25 2010-05-19 Novo Nordisk Health Care Ag Polipeptidos del factor de coagulacion humano vii.
ATE505487T1 (de) * 2002-09-30 2011-04-15 Bayer Healthcare Llc Fvii- oder fviia-varianten mit erhöhter koagulationswirkung
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
CN104630192A (zh) 2002-10-02 2015-05-20 催化剂生物科学有限公司 制备与筛选改变特异性蛋白酶的方法
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
EP3103869A1 (en) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
CA2528239A1 (en) 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
WO2004110469A2 (en) 2003-06-13 2004-12-23 Novo Nordisk Health Care Ag Formulations comprising factor viia and a factor vii related polypeptide
ES2373658T3 (es) 2003-06-18 2012-02-07 Bayer Pharma Aktiengesellschaft Nuevas entidades biológicas y el uso de las mismas.
AU2004249904A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
CN1863908B (zh) * 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005024006A2 (en) 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP1673453A2 (en) 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
WO2005051289A2 (en) 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
WO2005068620A1 (en) 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
WO2005075635A2 (en) 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
WO2005100556A2 (en) 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
WO2005123119A2 (en) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
WO2005123916A2 (en) 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Glycosylation-disrupted factor vii variants
MXPA06015045A (es) 2004-06-21 2007-03-21 Novo Nordisk Healthcare Ag Uso del factor viia o equivalentes del factor viia para prevenir o atenuar el crecimiento de hemorragias y/o generacion de edemas despues de una hemorragia intracerebral.
US20060019893A1 (en) * 2004-07-02 2006-01-26 Genentech, Inc. Factor VIIa variants
WO2006008267A2 (en) 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
US20080108557A1 (en) 2004-09-29 2008-05-08 Novo Nordisk Healthcare A/G Modified Proteins
EP1827486A2 (en) 2004-12-22 2007-09-05 Direvo Biotech AG Targeted use of engineered enzymes
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
KR101364003B1 (ko) 2005-04-28 2014-02-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 활성화된 제ｖｉｉ 인자 폴리펩타이드를 포함하는 밀폐용기와 이의 제조방법 및, 키트와 키트의 사용방법
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
EP1893631B1 (en) 2005-06-17 2013-08-14 Novo Nordisk Health Care AG Dimeric and multimeric fviia compounds
WO2007022784A2 (en) 2005-08-26 2007-03-01 Maxygen Holdings Ltd. Liquid factor vii composition
US20080268521A1 (en) 2005-09-01 2008-10-30 Novo Nordisk Healthcare A/G Purification of Coagulation Factor VII Polypeptides
WO2007039475A1 (en) 2005-09-21 2007-04-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US20090221484A1 (en) 2005-10-07 2009-09-03 Novo Nordisk A/S Use of Factor VII Polypeptides for Neuroprotection
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
AU2007307260B2 (en) 2006-07-05 2013-02-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
WO2008009634A2 (en) 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
EP2114379A2 (en) 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
UA101155C2 (ru) 2007-04-13 2013-03-11 Каталист Байосайенс, Инк. Модифицированный полипептид фактора vii (fvii) и его применение
US9102962B2 (en) 2007-10-16 2015-08-11 Shiu Nan Chen Production method for solid cultured active mushroom mycelium and fruit-body metabolites (AMFM) products thereof
US8266208B2 (en) 2008-11-06 2012-09-11 Joseph Mahon Method and system for sharing documents among members of an online community
ES2524974T3 (es) * 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
CN201753815U (zh) 2010-07-27 2011-03-02 江森自控空调冷冻设备(无锡)有限公司 三通结构
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
EP2906693A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
CN1400910A (zh) * 2000-02-11 2003-03-05 马克西根公司 凝血因子VⅡ或VⅡa样分子
EP1644504A1 (en) * 2003-06-19 2006-04-12 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited FACTOR VII OR VIIa GLA DOMAIN VARIANTS
WO2007022512A3 (en) * 2005-08-19 2007-10-04 Neose Technologies Inc Glycopegylated factor vii and factor viia
WO2007031559A3 (en) * 2005-09-14 2007-11-08 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
WO2009090215A1 (en) * 2008-01-18 2009-07-23 Ge Healthcare Uk Limited Multiplex cell signalling assay
CN102083971A (zh) * 2008-04-11 2011-06-01 催化剂生物科学公司 修饰的因子ⅶ多肽及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRAIG D. DICKINSON et al..Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa..《Proceedings of the National Academy of Sciences of the United Stated of America》.1996,(第93期),14379–14384. *
Egon Persson et al..Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity..《Proceedings of the National Academy of Sciences of the United Stated of America》.2001,(第98期),13583–13588. *
Jais R. Bjelke et al..A loop of coagulation factor VIIa influencing macromolecular substrate specificity..《FEBS LETTERS》.2007,(第251期),全文. *

Also Published As

Publication number Publication date
AU2009234390B2 (en) 2013-10-31
JP2015017093A (ja) 2015-01-29
SG190560A1 (en) 2013-06-28
PL2281037T3 (pl) 2016-05-31
SG193779A1 (en) 2013-10-30
CA2721038C (en) 2018-07-31
EA201301350A1 (ru) 2014-07-30
JP2011517942A (ja) 2011-06-23
TW201431877A (zh) 2014-08-16
HK1154273A1 (zh) 2012-04-13
ES2560236T3 (es) 2016-02-18
HK1192905A1 (en) 2014-09-05
EA020818B1 (ru) 2015-02-27
AU2009234390A1 (en) 2009-10-15
EA024760B1 (ru) 2016-10-31
DK2281037T3 (en) 2016-01-11
KR101623602B1 (ko) 2016-06-07
CN105039291A (zh) 2015-11-11
TWI465247B (zh) 2014-12-21
EP2281037B1 (en) 2015-11-11
SI2281037T1 (sl) 2016-02-29
CO6331368A2 (es) 2011-10-20
US9476037B2 (en) 2016-10-25
JP5976021B2 (ja) 2016-08-23
HK1194096A1 (en) 2014-10-10
US20160376577A1 (en) 2016-12-29
TW200942258A (en) 2009-10-16
JP2014113157A (ja) 2014-06-26
BRPI0911060B1 (pt) 2022-04-05
IL225740A0 (en) 2013-06-27
US8519103B2 (en) 2013-08-27
CA2721038A1 (en) 2009-10-15
ES2556596T3 (es) 2016-01-19
ES2577055T3 (es) 2016-07-12
US20140044701A1 (en) 2014-02-13
PT2281037E (pt) 2016-01-27
NZ588322A (en) 2012-03-30
EP2281037A2 (en) 2011-02-09
JP5659312B1 (ja) 2015-01-28
US11203749B2 (en) 2021-12-21
EP2687596A2 (en) 2014-01-22
WO2009126307A3 (en) 2009-12-10
EP2679678A1 (en) 2014-01-01
TWI538916B (zh) 2016-06-21
EP2687596B1 (en) 2016-01-06
KR20110008084A (ko) 2011-01-25
MX344220B (es) 2016-12-07
BRPI0911060A2 (pt) 2015-10-13
WO2009126307A2 (en) 2009-10-15
HUE026937T2 (en) 2016-07-28
IL208373A0 (en) 2010-12-30
EA201001628A1 (ru) 2011-06-30
DK2687596T3 (da) 2016-02-29
MX2010011170A (es) 2010-11-01
MY161581A (en) 2017-04-28
US20090291890A1 (en) 2009-11-26
CN102083971A (zh) 2011-06-01
US20190055534A1 (en) 2019-02-21
IL208373A (en) 2014-07-31
EP2687596A3 (en) 2014-04-23
US10160961B2 (en) 2018-12-25
EP2679678B1 (en) 2016-05-18
EP3064580A1 (en) 2016-09-07
IL225740A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CN102083971B (zh) 修饰的因子ⅶ多肽及其应用
CN101743309B (zh) 修饰的因子ⅶ多肽及其应用
AU2013203608B2 (en) Factor vii polypeptides that are modified and uses thereof
HK1227434A (en) Factor vii polypeptides that are modified and uses thereof
HK1227434A1 (en) Factor vii polypeptides that are modified and uses thereof
HK1154273B (en) Factor vii polypeptides that are modified and uses thereof
HK1194096B (en) Factor vii polypeptides that are modified and uses thereof
HK1192905B (en) Factor vii polypeptides that are modified and uses thereof
AU2015224596A1 (en) Factor vii polypeptides that are modified and uses thereof
HK1134520B (en) Modified factor vii polypeptides and uses thereof
HK1174059A (en) Modified factor vii polypeptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230614

Address after: Gyeonggi Do, South Korea

Patentee after: GC Biopharmaceutical Co.

Address before: California, USA

Patentee before: Catalyst Biosciences, Inc.